Global Siponimod Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Siponimod Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Siponimod, sold under the brand name Mayzent, is a selective sphingosine-1-phosphate receptor modulator for oral use that is used for multiple sclerosis (MS). It is intended for once-daily oral administration.
Siponimod report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Siponimod market is projected to reach US$ 967.9 million in 2029, increasing from US$ 357 million in 2022, with the CAGR of 13.2% during the period of 2024 to 2029. Demand from Retail Pharmacy and Hospital Pharmacy are the major drivers for the industry.
The Siponimod market is primarily driven by the increasing demand for effective treatments for multiple sclerosis (MS), specifically for secondary progressive forms of the disease. Siponimod is an oral medication that modulates sphingosine 1-phosphate receptors, aiming to slow down the progression of disability in MS patients. The growing prevalence of MS and the need for therapies that address the more advanced stages of the disease contribute to market growth. Moreover, the convenience of oral administration compared to injectable treatments and the potential for improved patient quality of life further propel adoption. However, challenges include potential side effects and the need for close monitoring of patients, particularly during the treatment initiation phase. Navigating regulatory requirements and competition in the MS treatment landscape, alongside addressing affordability and access barriers for a broader patient population, pose ongoing concerns. The market's success relies on continuous research to optimize dosing regimens, comprehensive patient education about potential benefits and risks, and collaborations between pharmaceutical companies, healthcare providers, and MS patient organizations to advance MS management while addressing the evolving challenges associated with Siponimod therapy.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Siponimod market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Novartis
Segment by Type
0.25mg
0.2mg
Retail Pharmacy
Hospital Pharmacy
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Siponimod market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Siponimod, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Siponimod industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Siponimod in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Siponimod introduction, etc. Siponimod Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Siponimod market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Siponimod report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Siponimod market is projected to reach US$ 967.9 million in 2029, increasing from US$ 357 million in 2022, with the CAGR of 13.2% during the period of 2024 to 2029. Demand from Retail Pharmacy and Hospital Pharmacy are the major drivers for the industry.
The Siponimod market is primarily driven by the increasing demand for effective treatments for multiple sclerosis (MS), specifically for secondary progressive forms of the disease. Siponimod is an oral medication that modulates sphingosine 1-phosphate receptors, aiming to slow down the progression of disability in MS patients. The growing prevalence of MS and the need for therapies that address the more advanced stages of the disease contribute to market growth. Moreover, the convenience of oral administration compared to injectable treatments and the potential for improved patient quality of life further propel adoption. However, challenges include potential side effects and the need for close monitoring of patients, particularly during the treatment initiation phase. Navigating regulatory requirements and competition in the MS treatment landscape, alongside addressing affordability and access barriers for a broader patient population, pose ongoing concerns. The market's success relies on continuous research to optimize dosing regimens, comprehensive patient education about potential benefits and risks, and collaborations between pharmaceutical companies, healthcare providers, and MS patient organizations to advance MS management while addressing the evolving challenges associated with Siponimod therapy.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Siponimod market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Novartis
Segment by Type
0.25mg
0.2mg
Segment by Application
Retail Pharmacy
Hospital Pharmacy
Other
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Siponimod market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Siponimod, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Siponimod industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Siponimod in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Siponimod introduction, etc. Siponimod Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Siponimod market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices